Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
BI

NASDAQ · BIOA

BioAge Labs, Inc.

Healthcare · Biotechnology

$6.29

Down-$0.07 (-1.10%)

Updated Oct 7, 2026, 6:03 AM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
458.05M
P/E ratio
-6.04
Dividend yield
0.00%
52-week range
$6.25 – $25.96
Volume
3.25M
Avg. volume
403.63K

Price performance · BIOA

BIOA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

BIOA closed at $6.29 after 21 trading sessions, down 33.05% for the selected period.

Last close
$6.29
Period change
-33.05%
Period low
$6.29
Period high
$9.40
Daily close
View OHLC price history
BIOA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$6.44$6.45$6.00$6.293.25M
Oct 5, 2026$6.65$6.65$6.25$6.36783.35K
Oct 2, 2026$6.92$6.92$6.47$6.61869.99K
Oct 1, 2026$7.06$7.17$6.70$6.81591.11K
Sep 30, 2026$7.20$7.26$6.97$7.09755.93K
Sep 29, 2026$7.19$7.27$7.07$7.14425.33K
Sep 28, 2026$7.11$7.425$6.96$7.18800.19K
Sep 25, 2026$7.26$7.295$7.03$7.05630.29K
Sep 24, 2026$7.79$7.88$7.19$7.211.01M
Sep 23, 2026$8.43$8.49$7.68$7.89618.47K
Sep 22, 2026$8.20$8.53$8.11$8.461.07M
Sep 21, 2026$8.07$8.10$7.73$8.09787.32K
Sep 18, 2026$8.07$8.2299$7.86$8.061.51M
Sep 17, 2026$7.85$8.36$7.70$8.09940.14K
Sep 16, 2026$8.21$8.275$7.62$7.75715.82K
Sep 15, 2026$8.48$8.50$8.02$8.18643.57K
Sep 14, 2026$8.52$8.635$8.39$8.48563.39K
Sep 11, 2026$8.71$8.89$8.28$8.49672.08K
Sep 10, 2026$9.07$9.07$8.60$8.65492.87K
Sep 9, 2026$9.38$9.40$9.02$9.17488.35K
Sep 8, 2026$9.60$9.645$9.3239$9.395388.07K

Latest BIOA news

The latest Smart Investors Daily articles mentioning BIOA.

Stock researchCompany · Overview

BIOA research

Overview

Company profile and research snapshot.

Company profile

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
BIOA recent ratings
DateFirmRatingTarget
Sep 9, 2026Roth CapitalBuy—
Sep 8, 2026BTIGBuy—
Aug 6, 2026BTIGBuy—
Aug 3, 2026BTIGBuy—
Jul 31, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: • ROTH Healthcare Opportunities Conference (New York, September 29, 2026): BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, A

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By